- Home
- CWK vs ARWR Comparison
CWK vs ARWR Comparison
Compare CWK & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWK
- ARWR
- Stock Information
- Founded
- CWK 1784
- ARWR 2003
- Country
- CWK United States
- ARWR United States
- Employees
- CWK N/A
- ARWR N/A
- Industry
- CWK Real Estate
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- CWK Finance
- ARWR Health Care
- Exchange
- CWK Nasdaq
- ARWR Nasdaq
- Market Cap
- CWK 1.9B
- ARWR 1.7B
- IPO Year
- CWK 2018
- ARWR 1993
- Fundamental
- Price
- CWK $8.28
- ARWR $11.24
- Analyst Decision
- CWK Hold
- ARWR Buy
- Analyst Count
- CWK 6
- ARWR 11
- Target Price
- CWK $12.75
- ARWR $41.44
- AVG Volume (30 Days)
- CWK 2.7M
- ARWR 2.3M
- Earning Date
- CWK 04-29-2025
- ARWR 05-08-2025
- Dividend Yield
- CWK N/A
- ARWR N/A
- EPS Growth
- CWK N/A
- ARWR N/A
- EPS
- CWK 0.56
- ARWR N/A
- Revenue
- CWK $9,446,500,000.00
- ARWR $2,500,000.00
- Revenue This Year
- CWK $5.68
- ARWR $4,380.43
- Revenue Next Year
- CWK $5.95
- ARWR $64.24
- P/E Ratio
- CWK $14.79
- ARWR N/A
- Revenue Growth
- CWK N/A
- ARWR N/A
- 52 Week Low
- CWK $7.64
- ARWR $9.57
- 52 Week High
- CWK $16.11
- ARWR $30.41
- Technical
- Relative Strength Index (RSI)
- CWK 30.38
- ARWR 38.40
- Support Level
- CWK $8.09
- ARWR $9.64
- Resistance Level
- CWK $8.41
- ARWR $12.93
- Average True Range (ATR)
- CWK 0.55
- ARWR 1.18
- MACD
- CWK -0.04
- ARWR 0.18
- Stochastic Oscillator
- CWK 23.44
- ARWR 43.21
About CWK Cushman & Wakefield plc
Cushman & Wakefield is one of the largest commercial real estate services firms in the world, with global headquarters in Chicago. The firm provides various real estate-related services to owners, occupiers, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such valuation, project management, and facilities management.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.